Exclusive Summary

• The product has obtained US FDA GMP certification and has been registered in the United States, indicating its qualification and experience to enter mainstream global markets.
• Donepezil is a widely recommended core drug for Alzheimer's disease, and the orally disintegrating tablet formulation significantly improves patient compliance, ensuring continuous global market demand.
• Compared to the originator drug and other generic tablets, the orally disintegrating tablet formulation offers a differentiated advantage in ease of swallowing and rapid disintegration, meeting the needs of specific patient populations.
• The cost advantage of the generic drug, combined with FDA GMP and US registration experience, serves as a key competitive factor for expanding international distribution networks.